Riskpilot← Back to searchSign inGet full accessCURIDA DIATEC AS
ASActiveOrg 950372737Martin Linges Vei 25, 1364 FornebuManufacture of other chemical products n.e.c. · NACE 2059Est. 198821 employeeswww.diatec.com
Revenue 2024
NOK 16,2M
-15% vs 2023
EBITDA margin
-330.8%
-31% vs 2023
Equity ratio
29.0%
Financial strength
Net profit 2024
NOK -57,5M
-19% vs 2023
| Revenue | NOK 16,2M | -15% |
| EBITDA | NOK -53,5M | -31% |
| Net profit | NOK -57,5M | -19% |
| Total assets | NOK 100,8M | +13% |
| Equity | NOK 29,3M | -20% |
| Employees | 21 | — |
Legal name
CURIDA DIATEC AS
Org number
950372737
Legal form
Aksjeselskap
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
12. desember 1988
Share capital
NOK 3 618 155
Employees
21 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap eller styrets leder alene.
Company purpose
Utføre tjenester innenfor medisinsk og veterinærmedisinsk forskning og analyse, samt utvikling, produksjon og salg av diagnostiske immunologiske og molekylærbiologiske reagenser. Selskapet utfører også kontraktproduksjon av legmidler for veterinær og human bruk.
Address
Martin Linges Vei 25, 1364 Fornebu
Phone
+4723696966
Email
diatec@diatec.com
Website
www.diatec.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 594 | 8 125 | 11 425 | 13 982 | 10 278 | 11 362 | 12 452 | 18 779 | 19 079 | 28 051 | 38 845 | 73 250 | 78 968 | 81 158 | 46 668 | 19 133 | 16 176 |
| Staff expenses | −3 209 | −4 247 | −5 321 | −6 941 | −6 461 | −5 217 | −4 959 | −5 725 | −6 655 | −9 631 | −10 102 | −16 793 | −22 402 | −32 468 | −32 764 | −33 257 | −30 277 |
| EBITDA | 728 | 284 | 2 328 | 1 732 | −1 053 | −269 | 371 | 2 531 | 2 677 | 3 713 | 7 894 | 12 003 | 8 639 | 13 105 | −9 727 | −40 910 | −53 517 |
| Depreciation & amort. | −4 | −20 | −85 | −143 | −263 | −670 | −746 | −768 | −677 | −1 244 | −1 298 | −1 533 | −1 880 | −3 350 | −3 183 | −4 433 | −5 731 |
| EBIT | 724 | 264 | 2 243 | 1 589 | −1 316 | −939 | −375 | 1 762 | 2 000 | 2 469 | 6 595 | 10 470 | 6 758 | 9 754 | −12 910 | −45 343 | −59 248 |
| Net financials | 38 | −76 | −68 | 40 | −20 | −154 | −335 | −185 | −187 | −54 | −15 | −2 665 | −1 311 | 73 | −215 | −433 | −2 982 |
| Profit before tax | 762 | 187 | 2 175 | 1 628 | −1 335 | −1 093 | −711 | 1 577 | 1 813 | 2 415 | 6 581 | 7 804 | 5 448 | 9 828 | −13 124 | −45 777 | −62 230 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | 387 | 537 | 639 | 1 300 | 1 583 | 1 158 | 1 889 | −2 963 | 2 580 | −4 696 |
| Net profit | 762 | 187 | 2 175 | 1 628 | −1 335 | −893 | −519 | 1 190 | 1 276 | 1 776 | 5 280 | 6 222 | 4 289 | 7 938 | −10 162 | −48 357 | −57 534 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 485 | 3 199 | 5 879 | 7 307 | 9 295 | 11 230 | 11 835 | 12 648 | 15 179 | 17 931 | 28 945 | 39 928 | 35 495 | 40 144 | 34 630 | 88 820 | 100 792 |
| Equity | 1 571 | 1 759 | 3 934 | 4 961 | 3 626 | 5 991 | 5 472 | 6 538 | 7 814 | 9 590 | 11 871 | 18 092 | 20 251 | 20 097 | 25 336 | 36 658 | 29 258 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 000 | 1 620 | 3 000 | 2 500 | 1 350 | 304 | 0 | 0 | 0 | 0 | 0 | 0 | 53 321 |
| Short-term debt | 914 | 1 441 | 1 945 | 2 346 | 4 669 | 3 618 | 3 363 | 3 611 | 6 015 | 8 037 | 17 074 | 21 835 | 15 244 | 20 047 | 9 295 | 52 162 | 13 032 |
| Total debt | 914 | 1 441 | 1 945 | 2 346 | 5 669 | 5 238 | 6 363 | 6 111 | 7 365 | 8 341 | 17 074 | 21 835 | 15 244 | 20 047 | 9 295 | 52 162 | 66 353 |
EBITDA margin
-330.8%
This company
15.8%
Market median
-2194% vs market
20082024
Equity ratio
29.0%
This company
38.2%
Market median
-24% vs market
20082024
Return on equity
-196.6%
This company
18.4%
Market median
-1168% vs market
20082024
Net profit margin
-355.7%
This company
8.1%
Market median
-4491% vs market
20082024
Asset turnover
0.16×
This company
1.12×
Market median
-86% vs market
20082024
Debt / equity
2.44×
This company
0.62×
Market median
-294% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AP Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
BK Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Curida Holding As | Company | 100.0% | 100.0% | 2024 |
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Curida Holding As
CURIDA DIATEC AS Board members of CURIDA DIATEC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Per Erik Larsson | Chief Executive Officer | 0 companies |
| Bjørn Kirkaas Pedersen | Chief Executive Officer | 0 companies |
| Thomas Andreas Schanke Wrede-Holm | Board of Directors | 0 companies |
| Gustav Gaudernack | Deputy Chairman | 0 companies |
| Peter Axel Sandberg | Board of Directors | 0 companies |
| Ole Jesper Dahlberg | Chairman | 0 companies |
| Bjørn Einar Kihl | Chairman | 0 companies |
| Terje Gabrielsen | Board of Directors | 0 companies |
| Henrik Romero Falch | Board of Directors | 0 companies |
| Mira Halvorsen Børstad | Board of Directors | 0 companies |